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(n= 4) or 10,000 IEq/kg × 2 (n= 4) of encapsulated neonatal porcine
islets in their peritoneal cavity by laparoscopy.
Although the study demonstrated signiﬁcant improvement in
HbA1c and reduction of hypoglycemic unawareness events with an
improved transplant estimated function (TEF) score for up to 2 years
post-transplant, the reduction of insulin dose was marginal or none.With the encouraging results of pancreatic islet allotransplantation,
increasing attention is being directed towards pig islet xenotransplanta-
tion, whichwould resolve the problem of islet supply (Markmann et al.,
2016; Ekser et al., 2012). Free (nonencapsulated) pig islets (eitherwild-
type or genetically-engineered) havemaintained normoglycemia in im-
munosuppressed diabetic nonhuman primates for N1 year (Park et al.,
2015). Immunoisolated (encapsulated) pig islets have maintained
normoglycemia in non-immunosuppressed diabetic nonhuman pri-
mates for up to 6 months (Dufrane et al., 2006).
Groth et al. performed the ﬁrst clinical islet xenotransplantation in
1994 using fetal porcine islet-like cell clusters placed under the kidney
capsule (Groth et al., 1994). Although clinical beneﬁt was not demon-
strated, evidence was provided by measurement of porcine C-peptide
that porcine islets could survive in the human body. The ﬁrst national-
ly-regulated clinical trial of intra-peritoneal alginate-poly-L-ornithine-
alginate (APA) encapsulated (neonatal) porcine islet xenotransplanta-
tion in nonimmunosuppressed diabetic patients was carried out in
New Zealand and was associated with some reduction in hypoglycemic
unawareness (Matsumoto et al., 2014). However, there was a lack of
correlation between the number of islets transplanted and the clinical
outcome; the transplantation of 5000 IEq/kgwas associatedwith better
results than of 15,000 or 20,000 IEq/kg.
In this issue of EBioMedicine, Matsumoto et al. report the second clin-
ical trial of nationally-regulated encapsulated porcine islet xenotrans-
plantation, conducted in Argentina (Matsumoto et al., 2016). From
their previous experience, the authors speculated that a large islet
mass was susceptible to injury from oxygen and/or nutrient insufﬁcien-
cy, resulting in cell death. To avoid this problem, the islets were
transplanted in two steps, with the second transplant being carried
out 3 months after the ﬁrst. In order to transplant a total of 10,000om.2016.08.034.
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. This is an open access article underIEq/kg or 20,000 IEq/kg, patients received either 5000 IEq/kg × 2
(Importantly, there was no evidence of complications from the transfer
of porcine endogenous retroviruses.)
Although this second carefully-supervised trial is a step forward in
the ﬁeld of clinical islet xenotransplantation, several aspects need
consideration before large-scale clinical trials will become justiﬁed
(van der Windt et al., 2012).
(i) The number of islets obtained from the source pigs
Neonatal pigs may have some advantages as sources of islets
(discussed by Nagaraju et al., 2015), one of which is their poten-
tial to proliferate after transplantation (which is not believed to
be the case with adult islets). Whether there was any evidence
that this occurred in the present studywas not reported. Howev-
er, it is reasonable to anticipate that ‘neonatal’ pigs (newborn to
5 days old)may provide a yield of up to 25,000 islets, and ‘young’
pigs (7–22 days old)may provide up to 30,000 islets. A 70 kg pa-
tient would therefore require 700,000 islets (70 × 10,000 IE/kg)
or, more likely, 1.4 million islets (70 × 20,000 IE/kg), indicating
that a single patient would require islets from approximately
25–50 piglets. With 8–12 piglets in each litter, this would be fea-
sible. If, however, there is conﬁrmed evidence of proliferation of
the islets after transplantation, the number of piglets required
may be fewer.
(ii) Encapsulation of pig islets and the immune response
Although the great theoretical advantage of the transplantation of
encapsulated islets is that exogenous immunosuppressive thera-
pymay not be required, the long-term viability of the encapsulat-
ed islets remains questionable. The dilemma in APA-based
encapsulated islets is that, if the islets are not revascularized,
they are likely to become exhausted (and die) from lack of nutri-
ents and oxygen, particularly as some ﬁbrin accumulates around
the capsules, possibly reducing their permeability. In contrast, if
the islets are revascularized, they are likely to become susceptible
to injury from an immune or inﬂammatory response. There is al-
ready evidence that APA-based microencapsulated porcine islets
induce an inﬂammatory response, upregulating inﬂammatorythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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crosis factor-α, IL-6, interferon-γ, macrophages, neutrophils,
and dendritic cells (Cooper et al., 2016). The great deﬁciency of
the present study is that the authors did not investigate whether
there was an immune response to the islets (or capsules), though
they speculated that microcapsules might shed xeno-antigens
which activate the recruitment of CD4+T cells and macrophages
around the capsule. It will be essential to determine whether
there is an immune response to the pig islets. If there is, either
modiﬁcation of the capsules or the administration of exogenous
immunosuppressive therapy will be necessary, unless the islets
can be completely protected by genetic manipulation of the pig.
Our own opinion is that it will be difﬁcult to totally protect the en-
capsulated islets from the effects of cytokines and chemokines and pos-
sibly other components of the immune response, and therefore some
immunosuppressive therapy may prove inevitable, thus negating the
major theoretical advantage of ‘immunoisolation’. Nevertheless, as the
number of pancreases from deceased humans that become available
will never sufﬁce to cure all patients with T1D, the pioneering studies
by Matsumoto and his colleagues are important and timely.
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